Share

France-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and Japan.

Lexicon will hold the rights to market telotristat etiprate in the US, Canada and Japan, which is being developed for the treatment of carcinoid syndrome.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Telotristat etiprate is an oral, small molecule inhibitor of tryptophan hydroxylase (TPH), which reduces peripheral serotonin production without affecting serotonin levels in the brain.

Lexicon CEO Lonnel Coats said: "This collaboration with Ipsen provides the opportunity to create added value for Lexicon and more effectively commercialize telotristat etiprate in markets around the world.

"Lexicon will hold the rights to market telotristat etiprate in the US, Canada and Japan, which is being developed for the treatment of carcinoid syndrome."

"Ipsen is a leader in the treatment of carcinoid syndrome and neuroendocrine tumours with Somatuline (lanreotide). Lexicon will benefit commercially from Ipsen’s substantial market presence in Europe and other countries in the licensed territory, and will benefit globally from coordination with Ipsen on medical and scientific matters."

See Also:

Lexicon is currently carrying out Phase III clinical trials of telotristat for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumours, which produce large amounts of serotonin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US Food and Drug Administration (FDA) granted fast track status and orphan drug designation for telotristat, while European Medicines Agency (EMA) awarded orphan drug designation.

Ipsen CEO Marc de Garidel said: "Ipsen is delighted to enter into a partnership with Lexicon in Europe and other countries."

Lexicon is eligible to receive more than $145m, including $23m upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones, as part of the financial terms of the agreement.

The firm is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.